Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Introduction: Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.

Clinical Trials

A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder

Phase 2

Completed

Conditions: Schizophrenia, Schizoaffective Disorder

Interventions: Drug: Risperidone
Drug: RO6889450
Drug: Placebo

First Posted Date: 2020-08-13

Last Posted Date: 2023-10-10

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 287

Registration Number: NCT04512066

Locations: 🇺🇸
CNRI - Los Angeles, LLC, Pico Rivera, California, United States
🇺🇸
Neuro-Behavioral Clinical Research, Inc., Canton, Ohio, United States
🇺🇸
Uptown Research Institute, Chicago, Illinois, United States

and more 36 locations

A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm

Phase 3

Active, not recruiting

Conditions: Diabetic Retinopathy

Interventions: Drug: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab
Drug: Intravitreal Ranibizumab 0.5 mg Injection

First Posted Date: 2020-08-07

Last Posted Date: 2025-01-17

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 174

Registration Number: NCT04503551

Locations: 🇺🇸
Retinal Consultants of Arizona;Opthalmology, Phoenix, Arizona, United States
🇺🇸
Retina Consultants of Orange County;Clinical Research, Fullerton, California, United States
🇺🇸
Jules Stein Eye Institute/ UCLA, Los Angeles, California, United States

and more 61 locations

A Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista

Phase 3

Active, not recruiting

Conditions: Carcinoma, Hepatocellular

Interventions: Drug: Atezolizumab
Drug: Bevacizumab

First Posted Date: 2020-07-27

Last Posted Date: 2024-05-14

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 152

Registration Number: NCT04487067

Locations: 🇮🇹
Arcispedale Santa Maria Nuova; Oncologia, Reggio Emilia, Emilia-Romagna, Italy
🇮🇹
Istituto Nazionale Dei Tumori; Dipartimento Chirurgia Generale - Unita' Trapianti Fegato, Milano, Lombardia, Italy
🇮🇹
Azienda Ospedaliera Di Rilievo Nazionale E Di Alta Specializzazione Garibaldi, Palermo, Sicilia, Italy

and more 18 locations

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants

Phase 1

Completed

Conditions: Autistic Disorder
Child Development Disorders, Pervasive
Neurodevelopmental Disorders
Mental Disorders
Autism Spectrum Disorder

Interventions: Drug: Placebo
Drug: RO6953958
Drug: Midazolam

First Posted Date: 2020-07-17

Last Posted Date: 2024-07-10

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 88

Registration Number: NCT04475848

Locations: 🇬🇧
Hammersmith Medicines Research; Central Middlesex Hospital, London, United Kingdom

Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy

Phase 3

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Cabozantinib
Drug: Docetaxel
Drug: Atezolizumab

First Posted Date: 2020-07-15

Last Posted Date: 2025-02-27

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 366

Registration Number: NCT04471428

Locations: 🇫🇷
Hôpital Saint Joseph, Marseille, France
🇯🇵
Hyogo Cancer Center, Hyogo, Japan
🇯🇵
Sendai Kousei Hospital, Miyagi, Japan

and more 82 locations

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)

Phase 2

Completed

Conditions: Early Breast Cancer

Interventions: Drug: Giredestrant
Drug: Anastrozole
Drug: Palbociclib
Procedure: Surgery

First Posted Date: 2020-06-18

Last Posted Date: 2023-02-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 221

Registration Number: NCT04436744

Locations: 🇺🇸
UCLA - Burbank, Burbank, California, United States
🇺🇸
UCLA Hematology/Oncology-San Luis Obispo, San Luis Obispo, California, United States
🇺🇸
Orlando Health Inc., Orlando, Florida, United States

and more 62 locations

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors

Phase 3

Active, not recruiting

Conditions: Severe Hemophilia A

Interventions: Drug: Emicizumab

First Posted Date: 2020-06-16

Last Posted Date: 2025-04-23

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 55

Registration Number: NCT04431726

Locations: 🇹🇷
Ondokuz Mayis Univ. Med. Fac., Samsun, Turkey
🇮🇹
AORN Santobono Pausilipon, Napoli, Campania, Italy
🇮🇹
AOU di Parma, Parma, Emilia-Romagna, Italy

and more 28 locations

A Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors

Phase 3

Active, not recruiting

Conditions: Paroxysmal Nocturnal Hemoglobinuria

Interventions: Drug: Crovalimab
Drug: Eculizumab

First Posted Date: 2020-06-16

Last Posted Date: 2025-05-01

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 204

Registration Number: NCT04434092

Locations: 🇵🇱
MTZ Clinical Research Powered by Pratia, Warszawa, Poland
🇫🇷
Centre Hospitalier Lyon Sud, Pierre-Bénite, France
🇩🇪
Universitaetsklinikum Ulm, Ulm, Germany

and more 58 locations

A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema

Phase 3

Completed

Conditions: Diabetic Macular Edema

Interventions: Drug: Faricimab
Other: Sham Procedure

First Posted Date: 2020-06-16

Last Posted Date: 2024-10-30

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 1479

Registration Number: NCT04432831

Locations: 🇺🇸
Barnet Dulaney Perkins Eye Center, Mesa, Arizona, United States
🇺🇸
Retinal Research Institute, LLC, Phoenix, Arizona, United States
🇺🇸
Arizona Retina and Vitreous Consultants, Phoenix, Arizona, United States

and more 315 locations

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors

Phase 3

Active, not recruiting

Conditions: Paroxysmal Nocturnal Hemoglobinuria

Interventions: Drug: Eculizumab
Drug: Crovalimab

First Posted Date: 2020-06-16

Last Posted Date: 2025-05-04

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 190

Registration Number: NCT04432584

Locations: 🇬🇷
Attikon University General Hospital, Athens, Greece
🇪🇸
Hospital Universitari Vall d'Hebron, Barcelona, Spain
🇪🇸
Hospital Universitario de Gran Canaria, Las Palmas, Spain

and more 77 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy